In-Pharmatechnologists -- Intercell has killed development of its Travellers’ Diarrhoea Vaccine Patch after the product failed in clinical trials which will lead to job cuts and a dramatic reduction of R&D expenses. The Austrian biotech firm said the decision was made after the candidate “did not meet the endpoints” in efficacy when it failed to protect against enterotoxigenic Escherichia coli (E coli) mediated diarrheal infections during a randomised and placebo-controlled Phase III study involving 2036 travellers.
